Acrivon Therapeutics (ACRV) Competitors $5.44 +0.37 (+7.30%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$5.45 +0.01 (+0.18%) As of 03/14/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ACRV vs. ABCL, CVAC, CRMD, ORGO, SION, QURE, NUVB, LENZ, CDXC, and KALVShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include AbCellera Biologics (ABCL), CureVac (CVAC), CorMedix (CRMD), Organogenesis (ORGO), Sionna Therapeutics (SION), uniQure (QURE), Nuvation Bio (NUVB), LENZ Therapeutics (LENZ), ChromaDex (CDXC), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. AbCellera Biologics CureVac CorMedix Organogenesis Sionna Therapeutics uniQure Nuvation Bio LENZ Therapeutics ChromaDex KalVista Pharmaceuticals AbCellera Biologics (NASDAQ:ABCL) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership. Do analysts rate ABCL or ACRV? AbCellera Biologics currently has a consensus target price of $7.00, suggesting a potential upside of 177.78%. Acrivon Therapeutics has a consensus target price of $23.67, suggesting a potential upside of 335.05%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than AbCellera Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Acrivon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, ABCL or ACRV? Acrivon Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbCellera Biologics$28.83M26.04-$146.40M-$0.55-4.58Acrivon TherapeuticsN/AN/A-$60.39M-$2.70-2.01 Does the media refer more to ABCL or ACRV? In the previous week, Acrivon Therapeutics had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 7 mentions for Acrivon Therapeutics and 3 mentions for AbCellera Biologics. Acrivon Therapeutics' average media sentiment score of 1.02 beat AbCellera Biologics' score of 0.10 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ABCL or ACRV more profitable? Acrivon Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AbCellera Biologics-533.32% -15.73% -12.22% Acrivon Therapeutics N/A -47.95%-43.73% Which has more risk & volatility, ABCL or ACRV? AbCellera Biologics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Do insiders & institutionals have more ownership in ABCL or ACRV? 61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 28.0% of AbCellera Biologics shares are owned by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer ABCL or ACRV? AbCellera Biologics received 20 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 97.22% of users gave Acrivon Therapeutics an outperform vote while only 75.34% of users gave AbCellera Biologics an outperform vote. CompanyUnderperformOutperformAbCellera BiologicsOutperform Votes5575.34% Underperform Votes1824.66% Acrivon TherapeuticsOutperform Votes3597.22% Underperform Votes12.78% SummaryAcrivon Therapeutics beats AbCellera Biologics on 11 of the 17 factors compared between the two stocks. Remove Ads Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$169.38M$7.03B$5.67B$8.14BDividend YieldN/A2.75%4.40%4.09%P/E Ratio-2.016.2923.9019.07Price / SalesN/A232.45395.2888.18Price / CashN/A65.6738.0534.64Price / Book1.016.596.834.29Net Income-$60.39M$142.18M$3.19B$247.48M7 Day Performance-1.81%-1.29%6.57%-0.84%1 Month Performance0.37%-8.94%-0.32%-9.35%1 Year Performance-12.12%-5.83%13.02%4.01% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics2.346 of 5 stars$5.44+7.3%$23.67+335.0%-12.1%$169.38MN/A-2.0158Short Interest ↓News CoveragePositive NewsGap UpABCLAbCellera Biologics2.2913 of 5 stars$2.20-5.6%$7.00+218.2%-46.5%$655.57M$28.83M-3.61500High Trading VolumeCVACCureVac3.8843 of 5 stars$2.92-3.9%$10.00+242.5%-8.8%$653.73M$543.28M5.31880CRMDCorMedix1.5368 of 5 stars$10.73+0.2%$16.00+49.1%+174.8%$651.06M$12.26M-13.2530ORGOOrganogenesis3.1777 of 5 stars$5.13-0.6%$5.50+7.2%+75.8%$650.63M$482.04M-85.50950SIONSionna TherapeuticsN/A$14.90-8.4%$38.50+158.4%N/A$633.56MN/A0.0035Quiet Period ExpirationNews CoverageQUREuniQure3.5412 of 5 stars$11.70-4.3%$38.89+232.4%+174.7%$632.70M$27.12M-2.36500Analyst UpgradePositive NewsNUVBNuvation Bio2.6647 of 5 stars$1.88-7.2%$8.00+326.7%-6.4%$631.06M$7.87M-0.8660Analyst UpgradeAnalyst RevisionNews CoverageLENZLENZ Therapeutics2.4015 of 5 stars$22.58-4.6%$35.40+56.8%N/A$620.97MN/A0.00110CDXCChromaDex4.0268 of 5 stars$7.88+2.3%$9.03+14.6%+226.7%$612.67M$99.60M788.79120Analyst RevisionKALVKalVista Pharmaceuticals4.4874 of 5 stars$11.99+0.6%$23.80+98.5%+5.6%$592.52MN/A-3.29100Analyst ForecastNews Coverage Remove Ads Related Companies and Tools Related Companies AbCellera Biologics Competitors CureVac Competitors CorMedix Competitors Organogenesis Competitors Sionna Therapeutics Competitors uniQure Competitors Nuvation Bio Competitors LENZ Therapeutics Competitors ChromaDex Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 3/16/2025 by MarketBeat.com Staff From Our PartnersTrump Shock to change everything Is this Trump’s next major move? Millionaire trading expert Imre Gams has found a bill that directs the Uni...Centurion Publishing | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
